Table 3 Selected ongoing clinical trials with BsAbs (alone and in combination) in RRMM.
From: Bispecific antibodies in the treatment of multiple myeloma
Trial | BsAb/BiTE | Patient group | No. of patients | Treatment | Primary endpoint | Status | Identifier |
|---|---|---|---|---|---|---|---|
MajesTEC-9 (Phase 3) | Teclistamab | 1–3 prior lines, including ≥2 consecutive cycles of anti-CD38MoAb and ≥consecutive cycles of Lenalidomide. Previous exposure to anti BCMA agents excluded | 590 | Teclistamab vs Pomalidomide-Bortezomib-Dexamethasone or Carfilzomib-Dexa | PFS | Recruiting | NCT05572515 |
MajesTEC-3 (Phase 3) | Teclistamab | 1–3 prior lines, including a PI and Len; participants who have received only 1 line of prior line of antimyeloma therapy must be Len refractory. Prior exposure to BCMA therapies excluded | 587 | Teclistamab-Daratumumab vs Dara-Bort-Dex or Dara-Pom-Dex | PFS | Not active | NCT05083169 |
MonumenTAL-6 (Phase 3) | Talquetamab Teclistamab | 1–4 prior lines, including anti-CD38MoAb and Lenalidomide | 795 | Talquetamab -Pomalidomide vs Talquetamab-Teclistamab vs Investigator choice of either Elotuzumab-Pomalidomide-Dexamethasone OR Pomalidomide-Bortezomib-Dexamethasone | PFS ORR | Recruiting | NCT06208150 |
MagnetisMM-4 (Phase 2) | Elranatamab | At least 3 prior lines of therapy. Refractory to atleast 1 IMiD, one PI and one CD38 Mo-Ab | 92 | Elranatamab - Nirogacestat vs Elranatamab-Lenalidomide- Dexamethasone | DLT, ORR | Recruiting | NCT05090566 |
MagnetisMM-5 (Phase 3) | Elranatamab | Prior anti-multiple myeloma therapy including treatment with Len and PI. Prior exposure to BCMA and prior exposure to CD38 MoAb within last 6 months are exclusions | 762 | Elranatamab vs Elranatamab- Daratumumab vs Dara-Pomalidomide-Dexamethasone | PFS | Recruiting | NCT05020236 |
LINKER MM-3 (Phase 3) | Linvoseltamab | At least 1 and no more than 4 prior lines, including Len and a PI and demonstrated disease progression on or after the last therapy. Participants who have received only 1 line of prior line of antimyeloma therapy must be Len refractory. Previous exposure to Elotuzumab or Pomalidomide are exclusions | 300 | Linvoseltamab vs Elotuzumab-Pomalidomide-Dexamethasone | PFS | Recruiting | NCT05730036 |
MagnetisMM-20 (Phase 1b) | Elranatamab | 1–3 lines for part 1. At least 3 lines for part 2, prior exposure to BCMA therapies excluded | 14 | Elranatamab with Carfilzomib-Dexamethasone and Maplirpacept | DLT | Recruiting | NCT05675449 |
NCT05137054 (Phase 1) | Linvoseltamab | At least 3 lines of therapy, rest cohort specific | 317 | Linvoseltamab – Daratumumab-Dexamethasone vs Linvoseltamab-Carfilzomib-Dexamethasone vs Linvoseltamab – Lenalidomide-Dexamethasone vs Linvoseltamab-Bortezomib-Dexamethasone | DLT, TAE, SAE | Recruiting | NCT05137054 |
NCT04108195 (Phase 1b) | Teclistamab Talquetamab | At least 3 lines of therapy | 289 | Teclistamab + Daratumumab vs Talquetamab + Daratumumab, then ±Pomalidomide | DLT | Active, not recruiting | NCT04108195 |
